Development and validation of a nomogram based on stromal score to predict progression‐free survival of patients with papillary thyroid carcinoma

Objective To detect the expression of FK506-binding protein 5 (FKBP5) in human papillary thyroid carcinoma (PTC) tissues, and explore its possible role in the progression of PTC. Methods FKBP5 expression levels were assessed in 115 PTC tissues and corresponding normal tissues by immunohistochemistry. We also examined the correlations between FKBP5 expression and clinicopathological factors and survival in 75 patients with PTC. The effects of FKBP5 on the proliferation and apoptosis of PTC cells were detected by colony-formation, MTT, and flow cytometry assays, respectively. We further investigated the effects of FKBP5 on tumor growth in mice. Results We revealed high expression levels of FKBP5 in human PTC tissues compared with normal tissues. Furthermore, high FKBP5 expression was associated with an increased incidence of intraglandular dissemination, and lower overall and progression-free survival. FKBP5 depletion remarkably suppressed the proliferation and induced apoptosis of PTC cells in vitro. FKBP5 further contributed to the growth of PTC tumors in mice. Conclusions The results of this study demonstrated the potential involvement of FKBP5 in the progression of PTC, and confirmed FKBP5 as a novel therapeutic target for PTC treatment.

Download Full-text

Development and validation of a novel 14-gene signature for predicting lymph node metastasis in papillary thyroid carcinoma

Gland Surgery ◽

10.21037/gs-21-361 ◽

2021 ◽

Vol 0 (0) ◽

pp. 0-0

Author(s):

Yuwei Ling ◽

Luyao Jia ◽

Kaifu Li ◽

Lina Zhang ◽

Yajun Wang ◽

...

Keyword(s):

Lymph Node ◽

Papillary Thyroid Carcinoma ◽

Lymph Node Metastasis ◽

Thyroid Carcinoma ◽

Gene Signature ◽

Papillary Thyroid ◽

Node Metastasis ◽

Development And Validation

Download Full-text

CD73 Overexpression Promotes Progression and Recurrence of Papillary Thyroid Carcinoma

Cancers ◽

10.3390/cancers12103042 ◽

2020 ◽

Vol 12 (10) ◽

pp. 3042 ◽

Cited By ~ 1

Author(s):

Young Mun Jeong ◽

Haejin Cho ◽

Tae-Min Kim ◽

Yourha Kim ◽

Sora Jeon ◽

...

Keyword(s):

Papillary Thyroid Carcinoma ◽

Thyroid Carcinoma ◽

High Expression ◽

Migration And Invasion ◽

Recurrence Free Survival ◽

Papillary Thyroid ◽

Tumor Immune Escape ◽

Free Survival ◽

Mesenchymal Transition ◽

Cd73 Expression

CD73 is involved in tumor immune escape and promotes the growth and progression of cancer cells. The functional role of CD73 expression in papillary thyroid carcinoma (PTC) has not yet been established. In 511 patients with PTC, immunohistochemistry for CD73 on tissue microarrays showed that the high expression of CD73 was associated with an aggressive histologic variant (p = 0.002), extrathyroidal extension (p < 0.001), lymph node metastasis (p < 0.001), and BRAFV600E mutation (p = 0.015). Survival analysis results showed that patients with high CD73 expression had worse recurrence-free survival (p = 0.023). CD73 inhibitors induced G1 cell cycle arrest and apoptosis, inhibited the migration and invasion of PTC cells, and suppressed tumor growth in PTC xenograft nude mice. High expression of CD73 (NT5E) mRNA was associated with unfavorable clinicopathologic characteristics, the abundance of Tregs and dendritic cells, depletion of natural killer (NK) cells, and high expression of immune checkpoint genes and epithelial-to-mesenchymal transition-related genes in The Cancer Genome Atlas (TCGA) dataset. Taken together, CD73 expression promotes tumor progression and predicts low recurrence-free survival. Targeting the CD73–adenosine axis in the tumor microenvironment offers an attractive pathway for therapeutic strategies aimed at advanced PTC.

Download Full-text

Efficacy and safety of lenvatinib in an elderly patient with metastatic papillary thyroid carcinoma and cardiological comorbidity: a case report

Future Oncology ◽

10.2217/fon-2019-0114 ◽

2019 ◽

Vol 15 (24s) ◽

pp. 27-33 ◽

Cited By ~ 1

Author(s):

Agnese Latorre ◽

Agnese Maria Fioretti ◽

Francesco Giotta ◽

Vito Lorusso

Keyword(s):

Atrial Fibrillation ◽

Thyroid Carcinoma ◽

Progression Free Survival ◽

Chronic Atrial Fibrillation ◽

Differentiated Thyroid Carcinoma ◽

Phase Iii ◽

Efficacy And Safety ◽

Papillary Thyroid ◽

Free Survival ◽

Select Trial

Lenvatinib significantly prolonged progression-free survival versus placebo in patients with radio-iodine refractory differentiated thyroid carcinoma. However, the primary adverse effects of any grade that occurred in >40% of patients in the lenvatinib group of the Phase III SELECT trial was hypertension (67.8%). Therefore, this drug should be used with caution in patients with cardiological morbidity. Here, we describe the case of a 73-year-old man with hypertension, obesity and chronic atrial fibrillation, who received lenvatinib for 6 months in the absence of cardiological symptoms.

Download Full-text

Is Completion Thyroidectomy Necessary in Patients with Papillary Thyroid Carcinoma who Underwent Lobectomy?

Korean Society for Head and Neck Oncology ◽

10.21593/kjhno/2021.37.2.25 ◽

2021 ◽

Vol 37 (2) ◽

pp. 25-31

Author(s):

Il Ku Kang ◽

Kwangsoon Kim ◽

Ja Seong Bae ◽

Jeong Soo Kim

Keyword(s):

Papillary Thyroid Carcinoma ◽

Thyroid Carcinoma ◽

Lymph Nodes ◽

Disease Free Survival ◽

Completion Thyroidectomy ◽

Papillary Thyroid ◽

Free Survival ◽

Disease Free ◽

Positive Lymph Nodes

Background/Objectives: Although thyroid lobectomy recently is considered as sufficient for low-risk papillary thyroid carcinoma (PTC), completion thyroidectomy is required due to the insufficiency of the preoperative evaluation. The aim of this study was to investigate recurrence rate and disease free survival depending on the gross extrathyroidal extension (gETE) or the number of metastatic lymph node identified in patients with PTC.Materials & Methods: We assessed 3373 patients with PTC who underwent lobectomy at Seoul St. Mary’s Hospital (Seoul, Korea) between January 2009 and December 2014. Clinicopathological characteristics and long-term surgical outcomes were retrospectively analyzed through complete chart reviews. The mean follow-up duration was 97.1 ± 21.4 months.Results: The rate of recurrence was higher in gETE group (1.8% vs. 6.0%, p=0.004), leading to decreased disease free survival in Kaplan-Meier analysis (log-rank p<0.001). N1 group (n=1389) was analyzed into two groups whether the number of positive nodes is more than 5 or less. For the group of the more metastatic nodes, the recurrence rate higher compared to the other group (3.0% vs. 9.3%, p<0.001). DFS was longer in the group that had lesser metastatic nodes (log-rank p<0.001). However, in terms of N1 group over 1cm (n=492), No statistical difference was observed according to the number of positive lymph nodes (4.5% vs. 9.1%, p=0.092)Conclusion: When it comes to node positive PTC, Despite the number of positive lymph nodes was over 5, follow-up with no further surgery can be an option.

Download Full-text

BRAF V600E mutation in papillary thyroid carcinoma: it’s relation to clinical features and oncologic outcomes in a single cancer centre experience

Endocrine Connections ◽

10.1530/ec-21-0410 ◽

2021 ◽

Author(s):

Mahmoud Al-Masri ◽

Tawfiq Al-Shobaki ◽

Hani Al-Najjar ◽

Rafal Iskanderian ◽

Enas Younis ◽

...

Keyword(s):

Overall Survival ◽

Papillary Thyroid Carcinoma ◽

Thyroid Carcinoma ◽

Disease Free Survival ◽

Braf V600e Mutation ◽

Braf V600e ◽

Cancer Center ◽

Papillary Thyroid ◽

Free Survival ◽

Disease Free

Purpose: This study focuses on the oncologic influence of BRAF V600E mutations in a cohort of Middle Eastern PTC patients treated at a single centre. We test the association of BRAFV600E mutation with papillary thyroid carcinoma at King Hussein Cancer Center. Methods: Patients with histologically confirmed PTC who underwent surgical treatment between 2006 and 2015 were included in this study. Oncological outcomes, both short and long termed were collected. Results: A total of 128 patients (68% females) were included in this study with a mean age of 38 years (±13.8). The median follow-up period was 50 months. The BRAF V600E mutation was found in 71% of patients. The tumor size for patients with a negative BRAF V600E mutation were significantly larger in comparison to patients who tested positive for the mutation (3.47 cm versus 2.31 cm, respectively, P = 0.009). The two groups showed similar disease-free survival (DFS) rates; positive = 75% (median 43 months (0-168)) compared to 78% for the negative BRAF V600E mutation (median 38 months (3-142)) (P= 0.162, HR=0.731) Furthermore, both groups showed similar overall survival rates: positive = 94.5% (median 56 months (0-228)) compared to 94.6% for the negative BRAF V600E mutation (median 43 months (3-157)) (P = 0.941, HR= 0.940). Conclusion: BRAF V600E mutation had no effect on loco-regional recurrence, distant metastasis, overall survival or disease-free survival. These findings may be attributed to geographic variations or reflect that BRAF V600E may only serve as an indicator of poor prognosis in high risk groups.

Download Full-text

Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in intermediate-risk papillary thyroid carcinoma patients with low postoperative stimulated thyroglobulin (1-20 ng/ml) and non-structural or functional metastasis: study protocol for a randomized-controlled trial

10.21203/rs.3.rs-59344/v1 ◽

2021 ◽

Author(s):

Pan Chen ◽

Jia-Xin Luo ◽

Wei Ouyang ◽

Hui-Juan Feng ◽

Ju-Qing Wu ◽

...

Keyword(s):

Papillary Thyroid Carcinoma ◽

Thyroid Carcinoma ◽

Dose Group ◽

Low Dose ◽

Disease Free Survival ◽

High Dose Group ◽

High Dose ◽

Intermediate Risk ◽

Papillary Thyroid ◽

Free Survival

Abstract Background: For some intermediate risk papillary thyroid carcinoma patients, if there are structural metastases, reoperation is preferred. If there are functional metastases (131I avidity), they can be treated with high-dose radioactive iodine (131I). However, it is still controversial whether 131I ablation should be used and the determination of 131I dosage for another part of intermediate risk patients with non-structural or functional metastases, especially those with postoperative stimulated thyroglobulin (ps-Tg) 1-20 ng/ml. The aim of the present study is mainly to compare the 3-years disease-free survival between low-dose group (1.1 GBq) and high-dose group (3.7 GBq) in intermediate risk papillary thyroid carcinoma patients with non-structural or functional metastases and ps-Tg 1-20 ng/ml.Methods: A single-center, randomized, double-blind parallel controlled study is designed at the Zhujiang Hospital of Southern Medical University. Participants will be randomized to low-dose group (1.1 GBq) or high-dose group (3.7 GBq) in a 1:1 ratio. After orally receiving different dosage of 131I once on an empty stomach, all patients will return to our hospital every 3-12 months to be performed related inspection items. Discussion: We believe that the 3-year disease-free survival of low-dose group (1.1 GBq) may not be lower than that of high-dose group (3.7 GBq) in intermediate-risk thyroid papillary carcinoma patients with no structural or functional metastases and ps-Tg 1-20 ng/ml. Besides we expect to clarify whether there are apparent differences in successful remnant ablation, efficacy, progression-free survival, safety, and health economics evaluation between the two groups.Trial registration: ClinicalTrials.gov (https://clinicaltrials.gov/), ID: NCT04354324. Registered on 16 April, 2020.

Download Full-text

Ultrasonography-guided Radiofrequency Ablation for Solitary T1aN0M0 and T1bN0M0 Papillary Thyroid Carcinoma: A Retrospective Comparative Study

Acta Endocrinologica ◽

10.1530/eje-21-0580 ◽

2021 ◽

Author(s):

Jing Xiao ◽

Yan Zhang ◽

Lin Yan ◽

Mingbo Zhang ◽

Xinyang Li ◽

...

Keyword(s):

Radiofrequency Ablation ◽

Papillary Thyroid Carcinoma ◽

Thyroid Carcinoma ◽

Tumour Progression ◽

Survival Rates ◽

Recurrent Laryngeal Nerve Injury ◽

Papillary Thyroid ◽

Free Survival ◽

Institutional Review ◽

Retrospective Comparative Study

Objective Ultrasonography-guided radiofrequency ablation (RFA) is used to treat small low-risk papillary thyroid carcinoma (PTC), and has achieved favorable results. However, few studies have compared the outcomes of T1aN0M0 and T1bN0M0 PTC treated with ultrasonography-guided RFA. The objective of this study was to compare the outcomes of patients receiving RFA for solitary T1aN0M0 and T1bN0M0 PTC retrospectively. Methods Patients treated with RFA for solitary T1aN0M0 or T1bN0M0 PTC between April 2014 and December 2019 were retrospectively reviewed. All patients were ineligible for or refused surgery. Our institutional review board approved this study. A total of 262 patients were included after adjustment for propensity score matching between the T1a and T1b groups. Local tumour progression (LTP), LTP-free survival, post-treatment complications, change in tumor volume, and RFA-related parameters were compared between the two groups. Results The LTP rate was 3.82% in both groups, and the LTP and LTP-free survival rates did not significantly differ between the two groups. One patient in group T1b developed transient recurrent laryngeal nerve injury. Significant tumor shrinkage was observed during the follow-up. The rate of tumour disappearance rate was higher in group T1a than in group T1b (81.7% vs. 52.7%, P<0.001). During RFA, the output power and total energy were higher and the duration was significantly shorter in group T1b than in group T1a (P<0.001). Conclusions The outcomes of RFA for the treatment of T1aN0M0 and T1bN0M0 PTC were similar. Therefore, RFA may be an alternative to surgery for the treatment of T1bN0M0 and T1aN0M0 PTCs.

Download Full-text